Eli Lilly and Company (NYSE: LLY) on Tuesday reported higher earnings and revenues for the third quarter of 2022. The company also provided guidance for fiscal 2022.
The Indianapolis-based pharmaceutical company said its revenues moved up 2% year-over-year to $6.94 billion in the third quarter as worldwide volumes increased by 13%.
The positive top-line performance translated into a 12% increase in net earnings, on an adjusted basis, to $1.98 per share. Unadjusted profit increased to $1.45 billion or $1.61 per share from $1.11 billion or $1.22 per share in the third quarter of 2021.
Check this space to read management/analysts’ comments on Eli Lilly’s Q3 2022 earnings
“With four more launches expected by the end of next year and a potential major new indication for tirzepatide, Lilly continues to make progress for patients with unaddressed medical needs through our significant commitment to invest in R&D, welcome the best talent, and turn breakthroughs in our labs into medicines for people around the world,” said David Ricks, CEO of Eli Lilly.
Image and article originally from news.alphastreet.com. Read the original article here.